@prefix dc1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
bl:category bl:Disease .
sub:association a rdf:Statement;
rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
rdfs:label "alogliptin tablets are a dipeptidyl peptidase 4 dpp 4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 1 14 important limitations of use not for treatment of type 1 diabetes or diabetic ketoacidosis 1 1 alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 14 important limitations of use alogliptin tablets are not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis as it would not be effective in these settings";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "WtbHR3i+5ydBrvRDiyxAg3dRVyLz6Bt2rKWzY2rycP2eKJadAPvbDJI484YUJBidj0oCS9C6v3LKwDha7DQip8yHPJ+CymRhKWBmr9spZF0Rxf+sk6SFIrGPr9Z1AxF35dXKoIOYhfMKoZvZfuMBKe4aFmRPIrBm8djFDL7f4Os=";
npx:hasSignatureTarget this: .
this: dc1:created "2021-06-12T14:43:14.540+02:00"^^xsd:dateTime;
dc1:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}